Big pharma’s key second-quarter data
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Destiny’s date with a partner
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
